CD8A and systemic lupus erythematosus: Additionally, we evaluated the CD4+ and CD8+ T cell EBV-specific ELISPOT response in SLE patients with undetectable EBV DNA (n = 38; 55.9%) and detectable EBV DNA (n = 30; 44.1%).